Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Xian Libang Pharmaceutical Co., Ltd.
WARNING LETTER
•Xian Libang Pharmaceutical Co., Ltd.•July 30, 2009

Xian Libang Pharmaceutical Co., Ltd. – FDA Warning Letter, Jul 30, 2009

Record Details

On January 28, 2010, the FDA issued a Warning Letter to Xian Libang Pharmaceutical Co., Ltd. following a July 27-30, 2009 inspection of their API manufacturing facility in ShanXi, China. The inspection revealed significant CGMP deviations, rendering their APIs adulterated under 21 U.S.C. 351(a)(2)(B).

Key violations included: 1. **Failure of quality unit to ensure proper material testing and reporting:** The firm used one infrared (IR) spectrum for a raw material lot to release two subsequent lots, raising concerns about data integrity. Laboratory records lacked complete raw data. 2. **Failure of quality unit to ensure CGMP compliance and detect data manipulation:** The quality control unit failed to detect substituted IR spectra by an employee. The firm fired the chemist responsible and removed the previous quality control and quality managers, but the response lacked a comprehensive plan to ensure data integrity. 3. **Failure to have adequate controls to prevent raw data manipulation:** A laboratory analyst modified printed raw data for IR spectra. The firm's response to install a server by September 30, 2009, was deemed inadequate without details on system configuration, procedures, and qualification.

The FDA requires a comprehensive corrective action plan addressing data integrity, including training for all personnel, a retrospective review of all test results, and an assessment of the impact of

Company
Xian Libang Pharmaceutical Co., Ltd.
Inspection date
July 30, 2009
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Richard L. Friedman (Director)
View Company Profile

ID · 6471769b-ae91-4f9d-80f5-02fa192f0bf8

Violation Codes4
21 U.S.C. 381(a)(3)FD&C Act 501(a)(2)(B)FD&C Act 801(a)(3)21 U.S.C. 351(a)(2)(B)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Xian Libang Pharmaceutical Co., Ltd.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.